CDSCO Draft Amendments and FDA QMSR Lead Major Developments for Global Manufacturers
NEW DELHI / WASHINGTON — The medical device regulatory landscape continues to evolve rapidly in 2026. India’s CDSCO has proposed significant amendments to the Medical Devices Rules, while the U.S. FDA has fully implemented its Quality Management System Regulation (QMSR). These updates affect compliance strategies, timelines, and costs for manufacturers worldwide.
Here’s a clear, up-to-date summary of the most important regulatory developments as of May 8, 2026.
India: CDSCO Draft Medical Devices (Amendment) Rules, 2026 (G.S.R. 270(E))
On April 10, 2026, the Ministry of Health and Family Welfare released draft amendments to the Medical Devices Rules, 2017. Stakeholders have until May 9, 2026 to submit comments.
Major Proposed Changes Include:
- Standardized Testing Fees: Introduction of a Ninth Schedule with fixed fees for government lab testing (e.g., implantation tests ₹5,000, sterility tests ₹2,000). Fees will increase by 5% annually.
- Sterilization Labeling: Manufacturers must clearly mention the licence number of the sterilization facility on product labels when outsourcing sterilization.
- Change in Constitution & Registration: Clarifications on handling changes in company constitution and registration certificate holders.
- Enhanced Transparency: Stronger requirements for traceability and compliance documentation.
Industry bodies like AiMeD have raised concerns over potential cost increases and implementation challenges, particularly for smaller manufacturers.
Other Recent India Updates:
- Continued rollout of risk-based classification refinements on the SUGAM Portal.
- Stronger emphasis on ISO 13485 compliance and post-market surveillance.
- Integration improvements between SUGAM and the National Single Window System (NSWS).
USA: FDA Quality Management System Regulation (QMSR) Fully Effective
Since February 2, 2026, the FDA has replaced the old Quality System Regulation (21 CFR Part 820) with the new QMSR. This aligns U.S. requirements more closely with ISO 13485:2016.
Key impacts:
- Manufacturers must ensure their Quality Management Systems meet the harmonized international standard.
- FDA inspections now follow updated protocols aligned with QMSR.
- Reduced redundancy for companies already ISO 13485 certified.
Additional FDA 2026 Developments:
- Updated guidance on Clinical Decision Support (CDS) software and General Wellness devices (January 2026) — expanding exemptions for certain digital health tools.
- Enhanced cybersecurity expectations in premarket submissions.
- New guidances on patient-matched orthopedic implants and AI-enabled devices.
Global Implications for Manufacturers
For U.S. companies exporting to India:
- Every imported device now requires a formal import license via the SUGAM Portal.
- Early preparation for the pending amendments on testing fees and labeling is critical.
For Indian manufacturers targeting the U.S. market:
- Alignment with the new FDA QMSR and ISO 13485 is more important than ever.
Practical Recommendations for 2026
- Review your device classification on the SUGAM Portal.
- Update labeling and QMS documentation to prepare for India’s draft amendments.
- Ensure ISO 13485 certification is current and aligned with FDA QMSR.
- Monitor the CDSCO website for the final version of the May 2026 amendments after the comment period ends.
- Engage regulatory consultants early for complex Class C/D devices or high-risk software as medical device (SaMD) products.
Looking Ahead
India is steadily strengthening its regulatory framework to match global standards while promoting domestic manufacturing. The U.S. continues its shift toward international harmonization and risk-based digital health oversight.
Manufacturers who proactively adapt to these changes will gain a significant competitive advantage in both markets.
FAQs
1. What is the deadline to comment on CDSCO’s draft Medical Devices Amendment Rules 2026? May 9, 2026 (30 days from publication on April 10).
2. When did the FDA QMSR become effective? February 2, 2026 — replacing the previous 21 CFR Part 820 requirements.
3. Do all medical devices imported into India need a CDSCO license in 2026? Yes. The SUGAM Portal process is now mandatory for virtually all imported devices.
4. What is the biggest change in India’s draft amendments? Introduction of fixed testing fees at government labs and mandatory sterilization facility licence number on labels.
5. How can manufacturers stay updated? Regularly check the official CDSCO website (cdsco.gov.in) and FDA CDRH updates.